)

Tharimmune (THAR) investor relations material
Tharimmune Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Clinical-stage biotech focused on immunology and inflammation, advancing TH104 for opioid overdose prophylaxis and pruritus in PBC, and developing early-stage immuno-oncology assets including bispecific antibodies and novel delivery platforms.
Positive FDA feedback received for TH104's new indication, enabling a 505(b)(2) NDA pathway with no additional clinical trials required for the lead program.
Multiple licensing agreements in place, including with Avior, Intract, and ABSI, supporting pipeline expansion and technology access.
Strategic focus on capital efficiency, partnerships, and potential M&A to maximize pipeline value.
Financial highlights
Net loss for Q2 2025 was $1.86 million, compared to $2.33 million in Q2 2024; net loss for the six months ended June 30, 2025 was $4.40 million, down from $4.58 million year-over-year.
Research and development expenses decreased 45% year-over-year to $0.55 million for Q2 2025, primarily due to lower pre-clinical and license fees, offset by higher stock-based compensation.
General and administrative expenses decreased 5% to $1.30 million for Q2 2025, with lower personnel costs partially offset by higher investor relations fees.
Cash and cash equivalents were $2.24 million as of June 30, 2025, down from $3.56 million at year-end 2024.
Accumulated deficit reached $41.3 million as of June 30, 2025.
Outlook and guidance
Substantial additional funding is required to support future operations; management has concluded that substantial doubt exists about the ability to continue as a going concern for at least one year.
Plans to seek additional capital through equity or debt offerings, partnerships, or grants, but no assurance of success or timing.
Focus remains on advancing TH104 regulatory filings and progressing CMC activities for NDA submission.
Next Tharimmune earnings date

Next Tharimmune earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage